Scheiner Zachary 4
4 · SpyGlass Pharma, Inc. · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
SpyGlass (SGP) Director Zachary Scheiner Receives 27,400-Share Award
What Happened
Zachary Scheiner, an Outside Director of SpyGlass Pharma, was granted a derivative award covering 27,400 shares on February 5, 2026. The grant shows a $0 acquisition price (award/option), so no cash was paid and the reported total value is $0. This is an equity grant under the issuer’s equity incentive plan, not an open-market purchase or sale.
Key Details
- Transaction date and price: 2026-02-05; 27,400 shares @ $0.00 (derivative award).
- Vesting: Subject to continuing service as an Outside Director; 1/36th of the shares vest monthly beginning on the Date of Grant (Feb 5, 2026). (Footnote F1)
- Beneficial ownership: Scheiner holds the option for the benefit of RA Capital funds and is obligated to turn over any net cash or stock received to the Adviser; he disclaims beneficial ownership of the option and underlying shares. (Footnote F2)
- Shares owned after transaction: Reporting person disclaims beneficial ownership of the option/underlying stock; the filing indicates the award is held for RA Capital funds.
- Filing timeliness: Report filed Feb 9, 2026 for a Feb 5 transaction — the Form 4 appears timely (filed within the required two business days).
Context
This was an equity award (derivative grant) with monthly vesting tied to continued service as an Outside Director. Because Scheiner disclaims beneficial ownership and holds the award for RA Capital funds (with proceeds to be turned over to the Adviser), this filing reflects a plan grant/arrangement rather than a direct personal purchase or sale.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1][F2]2026-02-05+27,400→ 27,400 totalExercise: $16.00Exp: 2036-02-05→ Common Stock (27,400 underlying)
Footnotes (2)
- [F1]Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.